Brief: Priovant Announces FDA Acceptance And Priority Review Of New Drug Application For Brepocitinib In Dermatomyositis
03/03/2026 12:45
March 3 (Reuters) - Roivant Sciences Ltd ROIV.O: PRIOVANT ANNOUNCES FDA ACCEPTANCE AND PRIORITY REVIEW OF NEW DRUG APPLICATION FOR BREPOCITINIB IN DERMATOMYOSITIS ROIVANT SCIENCES LTD - FDA ASSIGNS PDUFA DATE Q3 2026, LAUNCH EXPECTED SEPTEMBER 2026 Source text: ID:nGNX83tF0C Further company coverage: ROIV.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Roivant Sciences
See all newsU.S. STOCKS ON THE MOVE-Thermo Fisher, CME, Capital One, Northern Trust
Roivant rises as drug succeeds in two late-stage trials for eye disease
Immunovant falls after lupus drug setback
Brief: Roivant Announces Topline Results From Proof-Of-Concept Study Of Imvt-1402 In Cutaneous Lupus Erythematosus
U.S. STOCKS ON THE MOVE-Best Buy, Peloton, Apple